MiNK Therapeutics, Inc.
$12.82
▲
1.14%
2026-04-21 07:31:01
minktherapeutics.com
NCM: INKT
Explore MiNK Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$63.66 M
Current Price
$12.82
52W High / Low
$76 / $6.34
Stock P/E
—
Book Value
$-3.02
Dividend Yield
—
ROCE
859.68%
ROE
57.3%
Face Value
—
EPS
$-2.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.35
Debt / Equity
-0.25
Current Ratio
1.06
Quick Ratio
1.06
Forward P/E
-3.2
Price / Sales
—
Enterprise Value
$46.64 M
EV / EBITDA
-3.74
EV / Revenue
—
Rating
Strong Buy
Target Price
$39
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
| 2. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 3. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 4. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 5. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
| 6. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 7. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.28 M | -2.99 M | -3.69 M | -2.53 M | -2.21 M | — |
| Net Profit | -2.6 M | -2.89 M | -4.24 M | -2.77 M | -2.46 M | — |
| EPS in Rs | -0.52 | -0.58 | -0.85 | -0.56 | -0.5 | -0.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -12.49 M | -10.65 M | -22.92 M | -30.95 M |
| Net Profit | -12.49 M | -10.78 M | -22.46 M | -27.99 M |
| EPS in Rs | -2.52 | -2.17 | -4.52 | -5.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.24 M | 5.72 M | 4.55 M | 21.47 M |
| Total Liabilities | 28.47 M | 25.31 M | 22.61 M | 21.87 M |
| Equity | -14.23 M | -19.59 M | -18.06 M | -0.4 M |
| Current Assets | 13.85 M | 4.99 M | 3.6 M | 20.4 M |
| Current Liabilities | 13.03 M | 6.96 M | 11.4 M | 12.68 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.93 M | -9.56 M | -15.76 M | -18.87 M |
| Investing CF | — | 0 M | -0.07 M | -0.25 M |
| Financing CF | 14.72 M | 10.82 M | -0.41 M | -0.16 M |
| Free CF | -5.93 M | -9.56 M | -15.84 M | -19.12 M |
| Capex | — | — | -0.07 M | -0.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 51.98% | 19.77% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-01-28 | 1:0.1 |